Business
Grant of Options - Director/PDMR Shareholding
Grant of Options - Director/PDMR Shareholding.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n Evgen Pharma plc\n \n \n (\"Evgen\" or the \"Company\")\n \n \n \n \n \n \n Grant of Options\n \n \n \n Evgen Pharma plc (AIM: EVG), a clinical stage drug development company\n developing sulforaphane-based medicines\n \n announces that\n , on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility (\"PDMR\"), were granted nil cost options (the \"Options\") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company (\"Ordinary Shares\"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan (\"LTIP\").\n \n \n \n \n \n \n \n \n \n \n PDMR\n \n \n \n \n \n \n Position\n \n \n \n \n \n \n Current Ordinary Shares held\n \n \n \n \n \n \n Current Options held\n \n \n \n \n \n \n New options granted\n \n \n \n \n \n \n % of issued share capital including this award\n \n \n \n \n \n \n \n Dr Huw Jones\n \n \n \n \n CEO\n \n \n \n \n 62,500\n \n \n \n \n 4,648,890\n \n \n \n \n 4,410,727\n \n \n \n \n 3.3%\n \n \n \n \n \n \n Richard Moulson\n \n \n \n \n CFO\n \n \n \n \n 45,454\n \n \n \n \n 889,728\n \n \n \n \n 1,460,855\n \n \n \n \n \n \n \n 0.9%\n \n \n \n \n \n \n \n The Options will vest on the third anniversary of grant based on performance against challenging\n \n \n strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).\n \n \n \n \n \n Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.\n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n Evgen Pharma\n \n plc\n \n \n Dr Huw Jones, CEO \n \n Richard Moulson, CFO \n \n \n \n \n \n +44 1625 466591\n \n \n \n \n \n \n FinnCap (Nominated Advisor and Broker)\n \n \n \n \n \n Geoff Nash / Teddy Whiley (Corporate Finance)\n \n \n Alice Lane/Nigel Birks (ECM)\n \n \n \n \n \n +44 20 7220 0500\n \n \n \n \n \n \n Instinctif Partners\n \n \n Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon\n \n \n \n \n +44 207 457 2020\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n The information contained withi...